Class IV Laser in Non-invasive Laser
Therapy
Miroslav Prochazka, M. D., Head Doctor of the Private Rehab Clinic Jarov,
Prague, CZ
Mail
Abstract
The title must have awakened curiousness of every supporter
of non-invasive laser therapy, or at least a bit of amusement. Since
the very first small steps on the long and manifold path of laser medicine
we have been aware that despite dynamic development of this technique,
yet there is a couple of firm reference points. Laser will always mean
radiation of light with perfect coherence and monochromaticity. We will
never direct a laser in the eye and we will always mind also other contra-indications.
Lasers in class IIIa and IIIb are intended for applications in terms
of non-invasive laser therapy (LLLT), whilst class IV lasers are meant
for use in surgical specialties ... Or perhaps, maybe it is not quite
so ?
Output power is one of the most important parameters of a laser, indirectly
affecting also the spectrum of possible applications as well as time
required to perform therapy. Years back, low level laser therapy (LLLT)
manufacturers had provided devices fitting into class IIIa, often with
output power not exceeding 3 or 5 mW, especially HeNe sources which
were mainly used for superficial conditions, such as wound healing.
Expansion of application spectrum of LLLT into pain management and therapy
of locomotive apparatus clearly pointed to the need of higher output
levels and, similarly, led to implementation of other wavelengths with
deeper penetration in tissue (IR). Nowadays, therapists usually work
with infrared laser probes with 300 and more milliwatt of power, and
values of 450 - 500 mW represent an imaginary boundary for both manufacturers
and therapists, behind which laser devices are classified in laser class
IV, with all consequences in terms of hygienic rules and labour safety
applicable. There is no need to remark that hand in hand with increasing
output of non-invasive lasers, as well as due to long-term clinical
experience, higher and higher dosages of energy are also being administered.
Arndt-Schultz Law stipulates that effect of therapeutic laser appears
when a certain threshold limit of irradiated energy is exceeded, and
is rising till a level called plateau of effect is reached. As soon
as the plateau is reached, further increasing of energy dosage has allegedly
no influence on desired result of therapy. On the contrary, from a certain
level on (literature indicates ca 16 J/cm2) the effect of laser is purportedly
decreasing. However, in my opinion this applies only (though not quite
unequivocally) to in-vitro experiments with cellular cultures, not taking
into consideration (as it is practically impossible) the whole complex
of effects of laser on living organism within the frameworks of therapy
of a defined syndrome or complaint, comprising systematic effect, analgesic
and antalgic effect, antiphlogistic and vasodilatation effect, biostimulation
etc. Vice versa, in clinical practice it is obviously necessary to declare
that the higher dosage of energy is irradiated, the better therapeutic
effect is achieved. Furthermore, in case of deep seated applications
we must take into account substantial loss of energy in the course of
penetration of laser beam through tissue structures (skin, subcutaneous
fat, muscles, sinew, bone). That is why we have been meeting with significant
increase of recommended dosages of energy in treating deeply located
conditions. However, this is only a nominal increase; in fact the real
irradiated dosage of energy into the target structure is lower just
due to high absorption in tissue. Herat a certain sufficient real amount
of energy in the target area must be accomplished, which is unfortunately
something that can hardly be achieved working with lasers with too low
output power. Apart from that we have to note that higher output of
our device equals shorter therapy time, which is in terms of laser therapy
more than a substantive factor. Practical experience of our clinic,
which has been working as a supervisory and consultatory workplace for
almost the whole of the country, allows us to state that preponderance
of clinical fiascos of LLLT is caused by underdose.
Lack of power is something that surgical high power lasers surely do
not suffer from. In fact, any class IV surgical laser can be used for
therapeutic irradiation. Thus we are well familiar with Nd:YAG laser
inducing analgesic effects prior to a preparation in dentistry, or in
treatment of arthritis in rheumatology. Argon and KTP lasers are routinely
used for teeth whitening, though they have also been tested in dermatological
applications, such as treatment of psoriasis. Ruby laser had been used
by Endre Mester as the first laser for biostimulation and wound healing,
furthermore proving to be useful in healing up bed sores, varicose ulcers
and shingles. Excimer and Alexandrite lasers are capable of treating
some superficial dermatologic conditions, whilst high power diode lasers
can manage treatment of painful joint ailments. The advantage of all
those lasers is their ability to irradiate high dosages of energy on
large areas. However, it is necessary to defocus the beam or to scan
it over the skin so that concentration of high dosages of energy to
a little spot, leading to thermal damage of tissue, be eliminated. On
the other hand, high price of those lasers is a serious disadvantage,
almost disqualifying them economically for the use in laser therapy,
because comparable results can be obtained with lasers the price of
which is roughly 10 to 50 times lower.
Our clinic had also been using a CO2 surgical laser which was used in
co-operation with a dermatologist and a surgeon to handle various minor
excisions of superficial skin efflorescences. In several patients we
had also tried the effect of therapeutic irradiation in short application
times and from a distance. Those patients were suffering from torpid,
long lasting therapeutic interventions not affected by pain in joints
(especially with decompensated arthrosis) or sinews (epicondyllopathy).
We were able to irradiate values of hundreds of J/cm2 in time equal
to 5 - 10 seconds. Majority of patients treated in this way noticed
significant subjective relief after this therapy.
Recently we have had an opportunity to test a very interesting therapeutic
laser working with an output up to 4 Watts at the end of the probe.
This is a parameter classifying the device positively in class IV, with
all the conditions of operation resulting from that. Two semiconductor
diodes, each with 2 W output, working in 980 nm and 810 nm wavelengths
respectively, are the source of laser radiation. The manufacturer rationalizes
the use of the two wavelengths claiming that 810 nm penetrates as much
as into 8 cm depth in the tissue, whilst 980 nm wavelength is being
caught mainly in superficial layers of skin, thus inducing desired chain
of reflexive changes. Simultaneous application of both the wavelengths
in therapy thus contributes to optimizing therapeutic effect.
The laser can work in different frequency modes, and it is also possible
to set output power of the probe individually for every patient (in
1 mW increments within the range of 0 - 4.0 W). It is possible to use
two different frequency modes, either modulated or in pulses, the former
being intended for treating deeply seated pathological and painful conditions,
the latter used mainly for analgesic purposes. Combination of various
frequency modes is recommended, as well as combination of short point
treatments of the most painful spots with area irradiation of the whole
of the treated site with total irradiated amount of energy in the order
of hundreds of J/cm2.
The 980 nm wavelength induces a sense of warmness in treated patients;
therefore it is useful to carry out a simple "heat test" of
patient’s toleration. Patients should feel warmth after about
seven seconds of application of continuous beam, in this case an ideal
output power for a patient is set. In the course of initial application
we never continue in therapy in the event that the patient denotes subjective
unpleasant feelings. With regard to explicit thermal effect of this
therapy, practically always after irradiation a light erythema appears
on treated part of the body. No side effects of the therapy have been
noticed.
Therapy with a powerful laser with 4 W output and in special short-term
CW and frequency modes appears to be an interesting way to further development
of LLLT in pain management. A sophisticated device, utilizing a combination
of two IR wavelengths can prove its advantages in clinical use, especially
in treating patients where "classical" non-invasive lasers
do not achieve much clinical success. The price, which is substantially
higher than ordinary price of therapeutic lasers, although obviously
not reaching the amounts common for surgical lasers, may present a certain
obstacle in major expansion. Some applicants may also be discouraged
by the necessity to observe hygienic rules which are stricter for class
IV lasers when compared with rules for the use of common class IIIb
therapeutic lasers.
Laser therapy of human herpes simplex
lesions
By Arturo Guerra Alfonso and Pedro José Muñoz, Clinic
"Leonardo Fernández Sánchez" , Cienfuegos, Cuba.
Email
Herpes simplex is an illness caused by the human herpes
virus types 1 and 2 that generally present a primary lesion, with periods
of latency and a tendency to relapse. It is also known as Button
of fever or Bladder of fever. According to the World Health
Organisation (WHO) an international prevalence of about 60% is observed
(1, 2).
An experimental study was carried out, where
232 patients affected by the Herpes simplex type 1 virus were treated.
All patients attended the clinic "Leonardo Fernández" of the
area 3 of the municipality of Cienfuegos, during the period of January
2001 to January 2003, with the objective of determining the time of
recurrence of the labial Herpes in the groups, studied before and after
treatment, and to evaluate the effectiveness of the Laser of low power
in the treatment of the infection of the virus.
Two groups were selected (study and control)
with 116 patients in each group, distributed and classified according
to the clinical stage in which they went to consultation. In the study
group the patients were offered treatment with a LASERMED 670 DL, a
GaAlAs diode laser (30mW – 40 sec) in the prodromal stage and stage
of vesicles; or (20mW – 2 min) in the crust stage and in lesions infected
secondarily. To all these patients was also applied radiation among
the vertebras C2-C3 where the resident ganglion of the virus is located
during the latent periods (30mW - 30sec).
The control group was offered indicated treatment with
antivirals (Aciclovir in cream and in pills) and other palliative therapies.
After having carried out the analysis of the data obtained,
the following results were obtained:
Chart No. 1
The patients of the study group. Distribution according
to the frequency of annual recurrence of the labial herpes before and
after receiving treatment.
| Table No.1 |
|
|
|
|
|
|
|
|
| .
Distribution of the patients in the study group acc.
to the frequency of annual recurrence of herpes after laser therapy. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Study
group
n=116 |
Recurrence frequency |
|
| Once a month |
Every 2 to 3 months |
Every 4 to 5 months |
Every 6 month |
Once a year |
For the first time |
non recurrence |
|
| Befote
treatment |
9 |
26 |
58 |
12 |
7 |
4 |
_ |
|
| After
treatment |
_ |
_ |
37 |
22 |
25 |
_ |
32 |
|
When analyzing the chart No.1 it is observed that the
groups of patients that had Labial Herpes with high frequencies of recurrence
(after being treated with Laser and to wait one year to evaluate their
effectiveness), reported recurrence for more elongated periods of time
and 32 patients didn't even have any more recurrence.
Chart No.2
The patients of the control group. Distribution according
to the annual recurrence frequency of the labial herpes before and after
receiving treatment.
|
Control
group
n=116 |
Recurrence frequency after receiving treatment |
| Once a month |
Every 2 to 3 months |
Every 4 to 5 months |
Every 6 month |
Once a year |
For the first time |
non recurrence |
| Befote
treatment |
7 |
24 |
56 |
14 |
9 |
6 |
_ |
| After
treatment |
6 |
21 |
46 |
27 |
14 |
_ |
2 |
In the chart No. 2 the same previous aspects are reflected
but in the control group. As can be observed the cases diminished in
number, although discreetly; those that presented more recurrence and
of equal number of recurrencies increased in number of patient in the
periods of more lingering recurrence. In this group 2 patients reported
not to have had more lesions during the analyzed year.
Chart No.3
The patients of both groups. Distribution according to
the annual recurrence frequency of the labial herpes after receiving
treatment.
|
|
Recurrence frequency after
receiving treatment |
| Once a month |
Every 2 to 3 months |
Every 4 to 5 months |
Every 6 months |
Once a year |
non recurrence |
| Study
group
n=116 |
_ |
_ |
37 |
22 |
25 |
32 |
| Control
group
n=116 |
6 |
21 |
46 |
27 |
14 |
2 |
In the chart No. 3 are compared both groups as for the
annual frequency of recurrence after having received the corresponding
treatment. When analyzing this, the superiority of the group treated
with Laser becomes evident.
Chart No. 4
The patients' of both groups. Distribution with relationship
to the clinical stage in that we intervened and the time of cure of
the same ones.
| Clinical stage |
Time of cure |
| First 48h |
3 a 4 days |
5 a 7 days |
More than 7 days |
Total |
| No. |
% |
No. |
% |
No. |
% |
No. |
% |
|
| Study group
n=116 |
Prodromal |
26 |
100 |
_ |
_ |
_ |
_ |
_ |
_ |
26 |
| Vesicles |
40 |
95 |
2 |
4,8 |
_ |
_ |
_ |
_ |
42 |
| Crust |
31 |
91 |
3 |
8,8 |
_ |
_ |
_ |
_ |
34 |
| Secondary infection |
_ |
_ |
13 |
93 |
1 |
7,2 |
_ |
_ |
14 |
| Control group
n=116 |
Prodromal |
_ |
_ |
25 |
96 |
1 |
3,9 |
_ |
_ |
26 |
| Vesicles |
_ |
_ |
_ |
_ |
9 |
22 |
33 |
79 |
42 |
| Crust |
_ |
_ |
_ |
_ |
24 |
71 |
10 |
29 |
34 |
| Secondary infection |
_ |
_ |
_ |
_ |
_ |
_ |
14 |
100 |
14 |
| Total |
97 |
42 |
43 |
19 |
35 |
15 |
57 |
25 |
232 |
As can be observed in the chart 4, in the study group
100% of the prodromal stages, 95% of the vesicular ones and 91% of crust
stages were able to cure during the first 48 hours. The patients with
lesions infected secondarily needed more than 48 hours to cure, although
they never surpassed 5 days.
These results, although astonishing, are corroborated
by authors like Tunér and Schindl where they highlight that a treatment
with laser in the initial stages of the Labial Herpes has a percentage
of superior success compared to conventional treatments, besides achieving
an almost immediate relief of the symptoms (3, 11).
In the control group remarkable differences
are appreciated when comparing them with that of the study group. The
therapy with Aciclovir in early stages (the first 72 hours) has been
broadly suitable for many professionals and their use against the Labial
Herpes has been studied by some authors (5).
CONCLUSIONS
- The periods of annual recurrence in the study group
were prolonged considerably after having received the treatment, while
in the control group so evident changes were not shown.
- In the prodromal period the patients treated with Laser
all cured in the first 48 hours, while those treated conventionally
needed from 3 to 4 days to cure. - In the vesicular period and of crust, those of the
study group cured in majority during the first 48 hours, while those
of the control group needed more than 5 days.
- In infected lesions those treated with Laser cured
mainly from 3 to 4 days, while those treated with medications needed
more than 7 days to cure.
References:
1. Santana JC. Atlas of pathology of the buccal complex.
Havana: Editorial scientific-technique, 1985:30-34.
2. Eversole LR. Buccal pathology. Diagnosis and Treatment.
Havana: Editorial scientific-technique, 1985:82-87. 3. Tunér J, Hode L. Low level laser therapy - clinical
practice and scientific background. 1999. ISBN 91-630-7616-0.
4. Parker J et al. The effects of laser therapy on tissue
repair and pain control: a meta-analysis of the literature. Proc. Third
Congress World Assn for Laser Therapy, Athens, Greece, May 10-13 2000;
p. 77.
5. Vélez-González M et al. Treatment of relapse in herpes simplex on labial and
facial areas and of primary herpes simplex on genital areas and area
pudenda with low power HeNe-laser or Acyclovir administrated orally.
SPIE PROC. 1995; Vol. 2630: 43-50
6. Garrigó MI, Valiant C. Biological Effects of the radiation
Laser of low power in the repair hística. Rev. Cub Estomat, 1996; 33(2). 7. In: Simunovic Z, editor: Lasers in Medicine and Dentistry.
Vitagraf, Croatia, 2000.
8. Valiant C, Garrigó MI. Laser therapy in the treatment
of dental affections. Ed. Academy, Havana, 1995: 30-32.
9. Valiant C. Cuban Experience in the application of
the Laser of low power. I study international: Application of the Laser
of low power in dentistry. CIMEQ, City of Havana, April 2001.
10. Garrigó MI. Clinical procedures with Laser in bucodental
illnesses. I study international: Application of the Laser of low power
in dentistry. CIMEQ, City of Havana, 2001.
11.Schindl A, Neuman R. Low-intensity laser therapy is
an effective treatment forrecurrent herpes simplex infection. Results
from a randomized double-blind placebo-controlled study. J Invest Dermatol.
1999: 113 (2): 221-223.
CLINICAL EFFECTS OF FOCALISED AND DEFOCALISED
CO2 LASER ON EQUINE DISEASES
Arne Lindholm1, Ulf Swensson1, Eje Collinder2*
*1 Mälaren Equine Hospital, Hälgesta 1, S-193 91 Sigtuna,
Sweden
2 Microbiology and Tumor Biology Centre, Karolinska Institutet, von
Eulers väg 5, S-171 77 Stockholm, Sweden
ABSTRACT
CO2 laser has been used for five years at Mälaren Equine
Hospital, as an alternative treatment of some equine diseases. The application
of CO2 laser has been studied for evaluation of its appropriateness
for treatment of the equine diseases sarcoids, lameness in fetlock joints
or pulmonary haemorrhage. During the last five years, above 100 equine
sarcoids have been removed by laser surgery (CO2 laser) and so far resulting
in significantly few recurrences compared with results from usual excision
surgery. In one study, acute traumatic arthritis in fetlock joints was
treated three times every second day with defocalised CO2 laser. The
therapeutic effectiveness of CO2 laser in this study was better than
that of the customary therapy with betamethasone plus hyaluronan. During
one year, chronic pulmonary bleeders, namely exercise induced pulmonary
haemorrhage, has been treated with defocalised CO2 laser. Six racehorses
have been treated once daily during five days. Until now, three of these
horses have subsequently been successfully racing and no symptoms of
pulmonary haemorrhage have been observed.
These studies indicate that CO2 laser might be an appropriate therapy
on sarcoids and traumatic arthritis, and probably also on exercise induced
pulmonary haemorrhage. Other treatments for this pulmonary disease are
few.
INTRODUCTION
At Mälaren Equine Hospital, the last five years CO2 laser has been
used as an alternative for treatment of some equine diseases. For treatment
of the equine diseases sarcoids, traumatic arthritis in fetlock joints
and exercise induced pulmonary haemorrhage CO2 laser has been used as
described below. Clinical effects of these laser treatments are briefly
reported and if they might be appropriate modes of treatment.
CO2 LASER
The authors have used a CO2 laser, 25 W, with a scanning device, focalised
or defocalised. The laser consists of a CO2 emitter with a wavelength
of 10,600 nm. A visible Helium-Neon laser radiation (Wavelength 632.8
nm) superimposed on the CO2 emitter showing the area covered by the
laser beam. With the scanning device the beam of the guide light HeNe
and the CO2 laser can be transformed from the shape of a point into
a line. The user has to adjust and set the length of this “line”,
as well as the height of the movement, to cover the area of the tissue
to be treated. At the scanner there is a timer that automatically switches
off the radiation after the desired treatment time set by the user.
In that way, the scanning device automatically directs an equal amount
of radiation over the actual tissue. To achieve the desired amount of
radiation to the tissue per cm2, the user has to combine the following
parameters: Watt, time and tissue area. This scanner has the advantage
of being able to shed the radiation equally over the treated tissue
in a controlled manner to avoid the risk of side effects, such as burning,
or uncontrolled over/underexposure.
SARCOIDS
Equine sarcoids are defined as unique, benign, non-metastasising but
locally aggressive, fibroblastic skin tumours (1), but they have no
relation to human sarcoidosis (2). The etiology of sarcoids has been
contentious, but both epidemiology and clinical behaviour of sarcoids
strongly suggest the involvement of an infectious agent (both retroviruses
and papilloma viruses have been implicated), although numerous attempts
of isolation have met little reward. However, equine sarcoids are found
world-wide and comprise the most common tumour in equine practise. The
lesions appear solitary or multiple, sometimes at sites of previous
wounds. Although rarely pruritic or painful, the lesions have a reputation
for being notorious difficult to treat due to locally aggressive, infiltrative
growth, high rates of recurrence after excision, large size, multiple
lesions and/or localisation to sites compromising excision, like eyelids
(3). The clinical manifestations of sarcoids are very variable. Solitary
or multiple lesions can appear at any part of the body surface and growth
rate and size may vary from small, inactive nodules to large masses
of aggressive growing, secondary infected flesh, giving the impression
of infiltrating surrounding tissues. After the initial appearance, individual
sarcoids may retain static for years or fluctuate in size over a period
of time and occasionally regress, sometimes only to reappear later at
previous or new sites. Laser surgery has sometimes been used for treatment
of sarcoids (4).
The major problem associated with sarcoids in equine practise is the
high incidence of recurrence after surgery. The recurrence rate of approximately
50 % within three years after excision, of which the majority recurred
within six months, has been reported (5). Because of this great recurrence
after treatment with classical excision surgery we have used laser surgery
to remove 105 sarcoids during the last four years.
These sarcoids were situated on penis, preputium eyelids, close to eyes
and on the nose, back, neck and different other places in the skin.
The horses were tranquilised intramuscularly with detomidine, 0.5 ml
Domosedan® and butorphanol, 0.8 ml Torbugesic®. Thereafter the
skin was clipped and sterilised with alcohol after which a local anaesthesia
was performed with 2% Carbocain®
Method for laser incision: The body of the tumours were lifted up and
an articulated arm with a 125 mm handpiece at 25 Watts in a continuous
mode focalised to a spot light focus (0.2 mm spot size) was used back
and forth until the tumour was separated from its base. After removal
of the sarcoid the area site for the sarcoid and the skin edges were
sealed until complete haemostasis was achieved by heat. This heat was
achieved by using the handpiece laser defocalised, at a distance from
the tissue area that the spot size was 2-3 mm and coagulation took place.
The skin wound was left open without sutures. The wound was then kept
clean, but no other treatment was performed afterward.
Out of cases older than 6 moths, 25 % recurred and 75 % are recovered.
This material comprises mostly Swedish Warmbloods, mean age of the horses
was seven years and mean time for the wound after surgery to be healed
was ten days.
This result might indicate for further use of CO2 laser on sarcoids.
Especially when sarcoids are localised on troublesome sites for surgery
with a scalpel, such as eyelids, in the skin close to the eye-globe,
penis, preputium etc. - laser surgery should be the most successful
method.
TRAUMATIC ARTHRITIS
CO2 laser for treating traumatic arthritis in equine fetlock joints,
and their clinical effects, has been evaluated together with a comparison
with the effects of cortisone treatment. Before treatment, the horses
were placed in a stock under sedation with detomidine intramuscularly,
0.5 ml Domosedan® and butorphanol, 0.8 ml Torbugesic®. Our aim
was to estimate the clinical effects of the customary intra-articular
treatment with betamethasone (?M) plus hyaluronan (HA) and of CO2 laser,
as modes of treatment upon traumatic arthritis in fetlock joints. The
intra-articular dose of ?M was 2 ml Celeston® bifas®; 6 mg/ml,
the intra-articular dose of HA was 2 ml Hylartil© vet 10 mg/ml,
and the dose of the defocalised CO2 laser was 60 Joule/cm2 tissue surface;
six minutes per treatment lateral and medial. The joints were treated
three times: on day 1, 3 and 5. No pain or side effects from that laser
treatment were noticed.
Altogether, 144 horses constituted the experimental animals and 285
fetlock joints with acute traumatic arthritis were included; 114 fetlock
joints were treated with CO2 laser and 171 treated intra-articularly
with ?M + HA, which is the most common treatment of traumatic arthritis
in fetlock joints. Thereafter, the lameness of the treated fetlock joints
was re-evaluated 3-4 weeks after treatment. The recovered fetlock joints:
92 of the fetlock joints treated with CO2 laser, 80.7 %, and 116 of
the fetlock joints treated with ?M + HA, 67.8 %. This amount of recovered
joints after CO2 laser-treatment was significantly higher than that
after ?M + HA – treatment.
The authors assume that CO2 laser might be the best treatment for synovitis
in horses, particularly acute traumatic arthritis in fetlock joints.
The mechanism behind this effect of the laser treatment, however, remains
relatively unknown.
EXERCISE INDUCED PULMONARY HAEMORRHAGE
Until today, we have treated six race horses (4 Thoroughbreds, 2 Standardbreds)
diseased of so-called exercise induced pulmonary haemorrhage with defocalised
CO2 laser. Before treatment, the horses were placed in a stock under
sedation with detomidine intramuscularly, 0.5 ml Domosedan® and
butorphanol, 0.8 ml Torbugesic®. The dose of defocalised CO2 laser
was 60 Joule/ cm2 skin surface over each lung, corresponding to about
20 minutes/side. The lungs were treated once daily at 5 consecutive
days. This group of horses treated for exercise induced pulmonary haemorrhage
is interesting, but too small to draw finite conclusion from. However,
three of these horses have after laser treatment started and won race,
and this result may encourage us and/or others to use CO2 laser upon
this pulmonary disease, as other treatments are rare. In all horses
of this group, the number of macrophages decreased post treatment.
REFERENCES
1. Jackson, C. (1936) The incidence and pathology of tumors of domestic
animals in South Africa. Ondertepoort J. Vet. Sci. Anim. Ind. 6: 16;
241-248; 375-385; 429.
2. Stannard, A.A. and Pulley LT (1978) Tumors of the skin and soft tissues.
In: Tumors in Domestic Animals, 2nd ed, JE Moulton (ed), University
of California Press, Berkley, Los angeles, pp: 16-74.
3. Broström, H. (1995) Equine sarcoids. A clinical, epidemiological
and immunological study. Thesis, Swedish University of Agricultural
Sciences, Uppsala, Sweden.
4. Palmer, S.E. (1989) Carbon dioxide laser removal of a verrucous sarcoid
from the ear of a horse. JAVMA 195; 1125-1126.
5. Ragland, W.L. (1970) Equine sarcoid. Equine Vet. J. 2, 2-11.
*Correspondence author:
Eje Collinder
Microbiology and Tumor Biology Centre
Karolinska Institutet
von Eulers väg 5
S-171 77 Stockholm
Sweden
Bone Stimulation by Low Level Laser - A Theoretical
Model for the Effects
Philip Gable, B App Sc P.T. G Dip Sc Res (LLLT) MSc, Australia
Jan Tunér, D.D.S., Sweden
The anecdotal and researched evidence for the effects of Low Level Laser
Therapy (LLLT) on the stimulation of bone have been reported for over
20 years. This has been in the form of local as well as systematic effects
– including contra-lateral effects. Reports of stimulation of
rabbit radii fractures and mice femurs were made as early as 1986 and
1987 with irradiated bones healing faster than controls and contra-lateral
non-treated fractures similarly demonstrating faster healing times.
Over the following decade and a half, further studies have also investigated
and demonstrated that LLLT is effective for the stimulation of bone
tissue.
The reasons for this have been attributed to the general effects of
LLLT and its ability to increase the rates of healing through mitochondrial
ATP production and alteration in the cellular lipid bi-layer. Additional
hypothesis include the subsequent capacity of irradiated cells to alter
their ion exchange rate and thus influence the catalytic effects of
the specific enzymes and substrates. These in turn initiate and promote
the healing process completing the cascading cycle of events.
In the area of bone specific research, Dr. Tony Pohl of the Royal Adelaide
Hospital in South Australia, has provided a new theory that postulates
that the majority of fluid transfer and exchange within living bone
is predominantly influenced by the lymphatic circulation.
LLLT is well documented and known as having effects that influence the
lymphatic circulation and wound healing process. A coupling of these
two areas of theory can demonstrate a positive description and explanation
of the predominant effects of LLLT in bone stimulation. In reality,
LLLT’s effects on bone may well be a further consequence of its
actions on the lymphatic circulation.
Reports of stimulation of Rabbit radii fractures were made by Tang in
1986 and similar reports by Trelles in 1987 on mice femurs. In both
situations the irradiated bones healed faster than the controls. In
another study by Hernandez-Ros, in 1987, LLLT demonstrated stimulation
of fresh fractures on Sprague-Dawley rats that were fractured bilaterally.
The unexpected results of this study were that the contra-lateral fractured
non-treated limb also healed faster than the control group. Over the
following decade and a half further studies (Yamada 1991; Pyczek, Sopala
et al. 1994; Ozawa 1995; Horowitz 1996; Yaakobi 1996; Saito and Shimizu
1997) have also investigated and demonstrated that LLLT is effective
for promoting the stimulation of bone healing. Recently Nicolau and
colleagues (2002) from Brazil demonstrated the positive effect of LLLT
on the stimulation of bone in mice with latent promotion of bone remodulation
at injury sites without changes in bone architecture, increased bone
volume and increased osteoblast surface through increased resorption
and formation of bone with higher apposition rates. A positive effect
on bony implants has been demonstrated by Dörtbudak (2002) and
Guzzardella (2003). The effect of laser irradiation on osteoblastic
cells has been reported by Yamamoto (2001) and Guzzardella (2002).
The reasoning for this amelioration in all experimental circumstances,
based on electron microscopy as well as macroscopic histological evidence,
was concluded to be due to i.a. improved vascularisation as a consequence
of blood vessel formation, absorption of the haematoma, macrophage action,
fibroblast proliferation, chondrocyte activity, bone remodeling from
increased osteoblastic activity and deposition of calcium salts.
These changes and evidence based studies attribute the macro- and microscopic
effects to the known and accepted general actions of LLLT and its ability
to increase rates of healing through stimulation of ATP production,
(Karu 1989; Smith 1990) promoting repair and polarization of the cellular
lipid bilayer (Fenyo 1990) as well as LLLT’s capacity to affect
cells through alterations in their exchange rate of ions (Robinson and
Walters 1991) and influences the catalytic effects of the specific enzymes
and substrates (Pouyssegur 1985; Karu 1988) which in turn initiate and
promote the healing process.
More recent work by Dr. Tony Pohl, an internationally renowned Orthopaedic
Surgeon from the Royal Adelaide Hospital in South Australia and lecturer
at the Adelaide and South Australian Universities, has given rise to
a new theory on bone circulation through reconsideration of fluid and
protein transfer within bone (Pohl 1999). This theory suggests that
the general understanding of the circulatory action within bone has
been incorrect. Pohl postulates that the majority of fluid transfer
and exchange within the living bone is predominantly influenced by the
lymphatic rather than the vascular circulation. This is justified through
studies on bone fluid input and output levels that have demonstrated
that the venous and arterial aspect of circulation alone cannot account
for the demonstrated levels of output nor the presence of free radical
molecules which exceed those of the vascular input. Furthermore, the
diameter of large protein cells within the bone exceed the diameter
of the vessels that form the terminal aspects of the circulatory system
making it impossible for them to have been delivered via this system.
Consequently, an additional circulatory system must be present that
will account for both the increased output and the presence of the large
diameter protein cells as well as the free radicals.
If LLLT is then considered within the context of this new theory on
bone circulation and the contribution of the lymphatic circulation then
a further logical reasoned deduction for the action of LLLT on bone
stimulation can be made. LLLT has a well documented and known effect
influencing the lymphatic circulation. This has been demonstrated from
the early works of Lievens, (1985) that demonstrated the influence of
"Laser Irradiation" on the motricity of the lymphatic system
and on the wound healing process. This is supported by several wound
studies that demonstrate that the levels of protein rich exudates in
non-healing wounds increase markedly from exposure to LLLT. This demonstrated
action is determined to be as a result of the increase in lymphatic
circulation (Robinson and Walters 1991; Gabel 1995). More recent work
at the Flinders Medical Center in Adelaide South Australia has been
completed and presented at the World Association of Laser Therapy conference
in Tokyo Japan (Anderson, Carati et al. 2002). This study has demonstrated
the positive effects of LLLT on the lymphatic circulation and its consequential
benefits to the post mastectomy patient.
An understanding of the existing knowledge of the effects of LLLT on
the lymphatic system combined with the hypothesis of bone fluid transport
provides a coupled theory that would demonstrate a positive description
and explain of the predominant effects of LLLT in bone stimulation.
In the trauma situation of direct or indirect damage to the bone, including
fractures and periosteal induced damage such as stress fractures, the
tissue damage leads to compromises that include but are not limited
to, physical blockage from the trauma and waste / debris, increased
fluid and circulatory viscosity from added cellular content within the
lymphatics, lower speed motility and energy deficit in the tissue and
cells from the loss of ATP production as a general effect from the trauma,
cell changes and inability of mitochondria to function at the normal
higher level to promote self repair and regeneration.
LLLT with its known general effects and specific direct effects on the
lymphatic system would act to stimulate mitochondria ATP that increases
cellular and circulatory motility as well as directly influencing lymphatic
flow. LLLT also promotes increased permeability in interstitial tissue
and facial layers (Gabel 1995) reducing stagnation and blockage. These
actions would assist the increase in lymphatic flow and consequently
the circulation within the affected bone. There is also a hypothetical
potential that the presence of LLLT by increasing lymphatic circulation
does so by virtue of an increase in the diameter of the lymphatic vessels,
not just by increased flow rates within the vessel at an unchanged diameter.
This diameter increase, if definitively present, would also explain
the presence of large diameter protein cells within the normal bone
circulation that cannot be attributed to the vascular circulation and
would additionally explain a facilitated process for removal of debris
and larger protein cells passing out of traumatized areas that is additionally
stimulated by the use of LLLT.
Stimulation of bone healing by LLLT has till now has been generally
classified as a consequence of the general healing effects of LLLT.
In reality LLLT’s effect on bone may well be a further consequence
of its actions on the lymphatic circulation.
References:
Anderson, S, Carati, C et al. (2002). Low Level Laser
Therapy (LLLT) as a Treatment for Postmatestectomy Lymhoedema. WALT
2002, Tokyo Japan.
Coombe, A R et al (2001). The effect of low level
laser irradiation on osteoblastic cells. Clin Ort Res. 4: 3-14.
Dörtbudak, O et al (2002). Effect of low-power
laser irradiation on bony implant sites. Clin Oral Implants Res 13(3):288-292.
Fenyo, M. (1990). Theoretical and Experimental Basis of Biostimulation
by Bioptron, Bioptron AG, Monchaltorf, Switzerland.
Gabel, C. P. (1995). “Does Laser enhance bruising
in acute sporting injuries.” Aust. J. Physio. 41(4): 267-269.
Gabel, C. P. (1995). The effect of LLLT on slow healing
wounds and ulcers. Health Sciences. Darwin, Northern Territory.
Guzzardella, G A et al (2002). Laser stimulation on
bone defect healing: An in vitro study. Lasers Med Sci. 17(3): 216-220.
Guzzardella, G A et al (2003). Osseointegration of endosseous
ceramic implants after postoperative low-power laser stimulation: an
in vivo comparative study. Clin Oral Implants Res. 14: 226-232.
Horowitz, I. et al. (1996). “Infrared spectroscopy
analysis of the effect of low power laser irradiation on calvarial bone
defect healing in the rat (abstract).” Laser Therapy 8: 29.
Karu, T. I. (1988). “Molecular mechanism of the
therapeutic effects of low intensity laser radiation.” Lasers
in Life Science 2: 53-74.
Karu, T. I. (1989). Photobiology of low-power laser
therapy. London, Harwood Academic Publishers.
Lievens, P. (1985). The influence of "Laser Irradiation"
on the motricity of the lymphatical system and on the wound healing
process. International Congress on Laser in Medicine and Surgery., Bologna.
Nicolau, R A., Jorgetti, V, Rigau, J et al. "Effect
of low power laser Ga-Al-As (660nm) in the bone tissue remodulation
in mice”
Ozawa, Y. et al (1995). “Stimulatory effects of
low-power laser irradiation on bone formation in vitro.” SPIE
Proc. 1995 Vol. 1984: 281-288.
Pohl, T. (1999). Bone circulation, the lymphaitic system
contribution. Personal Communication to C. P. Gabel. Adelaide Oct 1999.
Pouyssegur, J. (1985). “The growth factor-activatable
Na+/H+ exchange system: a genetic approach. In Karu, T.I. 1988, 'Molecular
mechanism of the therapeutic effects of low intensity laser radiation',
Lasers in Life Science, vol.2, p.53-74.” Trends in Biochemical
Science 10: 453-455.
Pyczek, M., Sopala, M et al. (1994). “Effect of
low-energy laser power on the bone marrow of the rat.”. Folia
Biol (Krakow) 42(3-4): 151-156.
Robinson, B. and Walters, J (1991). “The use of
low level laser therapy in diabetic and other ulcerations.” Journal
of British Podiatric Medicine 46(10): 186-189.
Saito, S. and. Shimizu, N. (1997). “Stimulatory
effects of low-power laser irradiation on bone regeneration in midpalatal
suture during expansion in the rat.” Am J Ortod Dentofac Orthop
11(5): 525-.
Smith, K. C. (1990). Light and life: The photobiological
basis of the therapeutic use of radiation from lasers. International
Laser Therapy Association Conference, Osaka.
Yaakobi, T. et. al. (1996). “Promotion of bone
repair in the cortical bone of the tibia in rats by low energy laser
(He-Ne) irradiation.” Calcif Tissue Int. 59(4): 297-300.
Yamada, K. (1991). “Biological effects of low
power laser irradiation on clonal osteoblastic cells (MC3T3-E1).”
Nippon Seikeigeka Gakkai Zasshi 65(9): 787-799.
Yamamoto, M et al (2001). Stimulation of MCM3 gene expression
in osteoblast by low level laser irradiation. Laser in Med Sci. Abstract
issue. 16(3): 213-217.
|